Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases expression in the bronchial secretions of asthmatics and COPD Source: Eur Respir J 2002; 20: Suppl. 38, 92s Year: 2002
Matrix metalloproteinases in COPD Source: Eur Respir J 2012; 39: 197-209 Year: 2012
Matrix metalloproteinases in COPD Source: Eur Respir J 2011; 39: 197-209 Year: 2012
The influence of steroidotherapy in COPD exacerbation on matrix metalloproteinase MMP-9 level in BAL, induced sputum and serum Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004
Tissue inhibitor of metalloproteinases-;2 gene polymorphisms in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 748-752 Year: 2001
Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 521s Year: 2001
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Human macrophage elastase (MMP-12) expression in human emphysematous lungs: role in extracellular matrix remodelling in chronic obstructive pulmonary diseases (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019
MMP2, 8, 9 and TIMP1-4 levels in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease and bronchial asthma Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010
The expression of MMP2, 9 and TIMP1 mRNA in bronchoalveolar cells of patients with chronic obstructive pulmonary disease (COPD) and bronchial asthma Source: Annual Congress 2009 - New results in molecular pathology and functional genomics of non-neoplastic lung diseases Year: 2009
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007